AvidBiotics split forms CAR-T and antibiotic specialists – FierceBiotech
FierceBiotech |
AvidBiotics split forms CAR–T and antibiotic specialists
FierceBiotech Xyphos has its own spin on the CAR-T approach to cancer immunotherapy, which are targeted towards a single tumor-associated target. In contrast, the biotech's platform combines the modified T cells used in this type of treatment with bispecific … California upstart Xyphos wants to tackle CAR–T's big problems AvidBiotics Splits into Two Biotechnology Companies Each Developing its Distinct Technology Platform |
